WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

Core Insights - WuXi Biologics has successfully completed Asia's first commercial-scale Process Performance Qualification (PPQ) campaign for 5,000L single-use bioreactors, marking a significant advancement in biomanufacturing capabilities [1][3] - The company achieved a nearly 70% reduction in protein production costs per gram and a 20% increase in protein yield per batch through innovative process technologies [2][7] - The MFG20 facility's total capacity has increased from 8,000L to 23,000L by integrating three 5,000L single-use bioreactors with existing production lines [2][3] Company Achievements - WuXi Biologics has maintained a 99% production success rate over the past three years across over 300 batches of scaled production, demonstrating its leadership in commercial biomanufacturing [3] - The MFG20 facility has achieved a 100% PPQ success rate and holds ISO 14001 and ISO 45001 certifications, underscoring its operational excellence [3] - The company supports 817 integrated client projects, including 21 in commercial manufacturing, showcasing its extensive engagement in the biopharmaceutical sector [5] Sustainability and Innovation - WuXi Biologics emphasizes sustainability as a cornerstone of its long-term growth strategy, driving green technology innovations to provide advanced end-to-end Green CRDMO solutions [6] - The company is committed to fostering positive social and environmental impacts through responsible practices and collaboration with stakeholders [6]